Calcium-channel blockers and breast cancer: A hypothesis revived

JAMA Internal Medicine

Volumn 173, Issue 17, 2013, Pages 1637-1638

  Coogan, Patricia F ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESTROGEN RECEPTOR;

ATTRIBUTABLE RISK; BREAST CANCER; CANCER RISK; CLINICAL PRACTICE; DRUG INDICATION; HUMAN; HYPERTENSION; NOTE; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT DURATION;

ANTIHYPERTENSIVE AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; HYPERTENSION; POSTMENOPAUSE; RISK ASSESSMENT;

EID: 84884685366     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.9069     Document Type: Note

References (8)

1. Li CI, Daling JR, Tang M-TC, Haugen KL, Porter PL, Malone KE. Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years [published online August 5, 2013]. JAMA Intern Med. doi:10.1001/ jamainternmed.2013.9071.
2. Pahor M, Guralnik JM, Ferrucci L, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet. 1996;348(9026):493-497. (Pubitemid 26279010)
3. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer. 1997;80(8):1438-1447. (Pubitemid 27441018)
4. Singh A, Bangalore S. Which, if any, antihypertensive agents cause cancer? Curr Opin Cardiol. 2012;27(4):374-380.
5. Coogan PF. Non-hormonal medications and chronic diseases. In: Li CI, ed. Breast Cancer Epidemiology. New York, NY: Springer; 2010:243-260.
6. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997.
7. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356(9227):366-372. (Pubitemid 30487492)
8. Lindholm LH, Anderson H, Ekbom T, et al. Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet. 2001;358(9281):539-544. (Pubitemid 32772729)